Genomic Health (GHDX) Prelim. Q4, FY15 Revenues Miss Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations
January 8, 2016 8:00 AM ESTREDWOOD CITY, Calif., Jan. 8, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced preliminary revenue for the year ended December 31, 2015, is expected to be between $285 and $286 million, compared with $275.7 million in 2014, representing an increase of approximately 4 percent, slightly below the Company's 2015 guidance.
The Company delivered more than 106,850 Oncotype DX® tests in 2015, an increase of approximately 12 percent compared with 2014, within the Company's 2015 guidance.Â
For the fourth quarter 2015, the Company anticipates reporting between $73 and $74 million in revenue, representing an increase of approximately 6 percent compared to the fourth quarter of 2014, and more than... More
